A phase I/II study examining pentostatin, chlorambucil, and theophylline in patients with relapsed chronic lymphocytic leukemia and non-Hodgkin's lymphoma

Annals of Hematology
Carl R WillisIan W Flinn

Abstract

In an attempt to exploit bcl-2 overexpression and aberrant p53 function, two frequently encountered aberrations that predict marked treatment resistance and worse prognosis in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma (NHL), we combined theophylline, pentostatin, and chlorambucil at two dose levels (cohort I: 30 mg/m(2); cohort II: 20 mg/m(2)) on a 21-day cycle for up to six courses. We employed a phase I/II design to determine feasibility, define the maximum tolerated dose (MTD), and explore the impact of biologic modulation on response and time to progression (TTP) in 20 patients with relapsed or refractory CLL and NHL. Eight patients were enrolled in cohort I. They demonstrated a response rate (RR) of 28% and a 16.5-month TTP after receiving a median of two cycles. A 50% RR was observed in this cohort when patients with adverse histologies were excluded. Because of myelotoxicity, this dose level defined the MTD, and de-escalation occurred. All 12 patients in cohort II received 20 mg/m(2) chlorambucil. A 50% RR and an 18-month TTP were observed after a median of 5.5 cycles. An RR of 47% and a complete remission (CR) of 5% were observed for the entire group, although responses and TTP varied g...Continue Reading

References

Apr 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F J CummingsM J O'Connell
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R O DillmanO R McIntyre
Sep 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M R GreverS P Balcerzak
Aug 1, 1995·British Journal of Haematology·F MentzJ L Binet
Jan 1, 1993·Leukemia & Lymphoma·M J KeatingW Plunkett
Aug 21, 1997·The New England Journal of Medicine·A IchikawaT Hotta
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Dec 15, 2000·The New England Journal of Medicine·K R RaiC A Schiffer
Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM Keating
Mar 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mark A WeissDenise Horgan
May 20, 2003·British Journal of Haematology·Francis J GilesMaher Albitar

❮ Previous
Next ❯

Citations

Nov 27, 2008·Proceedings of the National Academy of Sciences of the United States of America·Lingzhi ZhangPaul A Insel
Jun 16, 2010·Leukemia & Lymphoma·Apostolia-Maria Tsimberidou, Michael J Keating
Jul 21, 2015·Chemistry and Physics of Lipids·Temilolu IdowuFrank Schweizer
Jul 27, 2007·Journal of Immunological Methods·H BlascoC Le Guellec
Jul 23, 2009·Chemistry & Biodiversity·Diana Florea-WangJari Hovinen
Sep 25, 2019·Cancers·Marcella CamiciMaria Grazia Tozzi
Nov 18, 2018·International Journal of Molecular Sciences·Mercedes Garcia-GilMaria Grazia Tozzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.